brenetafusp (IMC-F106C) News

|||||||||| brenetafusp (IMC-F106C) / Immunocore
Phase 1 safety and efficacy of brenetafusp, a PRAME (Exhibit Halls AB - George R. Brown Convention Center) - Oct 4, 2024 - Abstract #SITC2024SITC_1045;
Full Regular Abstract, Young Investigator Award (YIA), Immune Engineering Abstracts, and Late-breaking Abstract - Clinical Only (LBA) content will be embargoed until Nov. 5, 2024 at 8 a.m. CT / 9 a.m. ET

|||||||||| brenetafusp (IMC-F106C) / Immunocore
Single cell analysis of a T cell fitness signature associated with clinical benefit from brenetafusp, a PRAME x CD3 T cell engager (Exhibit Halls AB - George R. Brown Convention Center) - Oct 4, 2024 - Abstract #SITC2024SITC_809;
Full Regular Abstract, Young Investigator Award (YIA), Immune Engineering Abstracts, and Late-breaking Abstract - Clinical Only (LBA) content will be embargoed until Nov. 5, 2024 at 8 a.m. CT / 9 a.m. ET

|||||||||| Opdivo (nivolumab) / BMS, brenetafusp (IMC-F106C) / Immunocore
A phase 3 trial of IMC-F106C (PRAME x CD3) plus nivolumab versus standard nivolumab regimens in HLA-A*02:01+ patients with previously untreated advanced melanoma (PRISM-MEL-301). (Hall A; Poster Bd #: 384b) - Apr 24, 2024 - Abstract #ASCO2024ASCO_907;
P1/2, P3
5, 2024 at 8 a.m. CT / 9 a.m. ET T cell receptor (TCR) bispecifics have shown overall survival (OS) benefit with tebentafusp (gp100

|||||||||| brenetafusp (IMC-F106C) / Immunocore
Phase 1 safety and efficacy of IMC-F106C, a PRAME (Hall D1) - Apr 24, 2024 - Abstract #ASCO2024ASCO_825;
P1/2, P3
Clinical activity, measured by any confirmed tumor reduction and ctDNA molecular response, is enriched in PRAME+ patients at ~40% and associated with longer PFS and OS. IMC-F106C can be combined with anti-PD1.

||||||||||  brenetafusp (IMC-F106C) / Immunocore
Enrollment change, Trial completion date, Trial primary completion date, Combination therapy, Checkpoint inhibition:  IMC-F106C-101: Safety and Efficacy of IMC-F106C as a Single Agent and in Combination With Checkpoint Inhibitors (clinicaltrials.gov) -  Apr 4, 2024
P1/2, N=727, Recruiting,  Sponsor: Immunocore Ltd
IMC-F106C can be combined with anti-PD1. N=170 --> 727 | Trial completion date: Feb 2026 --> Jun 2026 | Trial primary completion date: Feb 2024 --> Jun 2026

||||||||||  brenetafusp (IMC-F106C) / Immunocore
Enrollment open, Metastases:  IMC-F106C Regimen Versus Nivolumab Regimens in Previously Untreated Advanced Melanoma (PRISM-MEL-301) (clinicaltrials.gov) -  Feb 19, 2024
P3, N=680, Recruiting,  Sponsor: Immunocore Ltd
N=170 --> 727 | Trial completion date: Feb 2026 --> Jun 2026 | Trial primary completion date: Feb 2024 --> Jun 2026 Not yet recruiting --> Recruiting

||||||||||  brenetafusp (IMC-F106C) / Immunocore
New P3 trial, Metastases:  IMC-F106C Regimen Versus Nivolumab Regimens in Previously Untreated Advanced Melanoma (PRISM-MEL-301) (clinicaltrials.gov) -  Oct 31, 2023
P3, N=680, Not yet recruiting,  Sponsor: Immunocore Ltd

|||||||||| IMC-F106C / Immunocore
Results from phase I dose escalation of IMC-F106C, the first PRAME × CD3 ImmTAC bispecific protein in solid tumors (7.2.F - Fécamp Auditorium) - Jul 25, 2022 - Abstract #ESMO2022ESMO_1375;
P1/2
Conclusions IMC-F106C, the first PRAME×CD3 ImmTAC, is well tolerated and demonstrated durable RECIST partial responses and ctDNA response in PRAME+ pts across multiple tumor types. Dose escalation and multiple expansions are ongoing.

||||||||||  brenetafusp (IMC-F106C) / Immunocore
Trial completion date, Trial primary completion date, Combination therapy, Checkpoint inhibition:  IMC-F106C-101: Safety and Efficacy of IMC-F106C as a Single Agent and in Combination With Checkpoint Inhibitors (clinicaltrials.gov) -  Mar 14, 2022
P1/2, N=170, Recruiting,  Sponsor: Immunocore Ltd
Dose escalation and multiple expansions are ongoing. Trial completion date: Feb 2024 --> Feb 2026 | Trial primary completion date: Feb 2022 --> Feb 2024

|||||||||| IMC-F106C / Immunocore
IMC-F106C, a novel and potent immunotherapy approach to treat PRAME expressing solid and hematologic tumors (Virtual Meeting II: E-Posters) - May 16, 2020 - Abstract #AACRII2020AACR-II_96;
In conjunction, IMC-F106C efficiently redirects T cell activity against tumor cell lines that express PRAME across a range of tumor indications. Taken together, IMC-F106C could prove to be a highly effective immunotherapy option for HLA*02:01 positive patients with PRAME positive tumors.

||||||||||  brenetafusp (IMC-F106C) / Immunocore
Enrollment open, Combination therapy, Checkpoint inhibition:  IMC-F106C-101: Safety and Efficacy of IMC-F106C as a Single Agent and in Combination With Checkpoint Inhibitors (clinicaltrials.gov) -  Feb 28, 2020
P1/2, N=170, Recruiting,  Sponsor: Immunocore Ltd
Taken together, IMC-F106C could prove to be a highly effective immunotherapy option for HLA*02:01 positive patients with PRAME positive tumors. Not yet recruiting --> Recruiting

||||||||||  brenetafusp (IMC-F106C) / Immunocore
New P1/2 trial, Combination therapy, Checkpoint inhibition:  IMC-F106C-101: Safety and Efficacy of IMC-F106C as a Single Agent and in Combination With Checkpoint Inhibitors (clinicaltrials.gov) -  Feb 9, 2020
P1/2, N=170, Not yet recruiting,  Sponsor: Immunocore Ltd



	Diseases Companies Products Productz Mechanisms of Action Sites